RTTNews) – AstraZeneca Plc. (AZN.L, AZN) said that its Imfinzi (durvalumab) has been recommended for marketing authorization in the European Union for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer in combination with chemotherapy …
Read More
About The Author
